You just read:

VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers

News provided by

VM BioPharma

Aug 03, 2017, 07:00 ET